Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place from September 14 to 16, 2026, in New York City. The fireside chat is scheduled for September 14 at 9 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of the company's investor relations website.
This participation is significant for Helus Pharma as it provides a platform to showcase its progress in developing treatments for major depressive disorder (MDD) and generalized anxiety disorder (GAD), areas with substantial unmet medical needs. The company's lead candidate, HLP003, is currently in Phase 3 clinical development for the adjunctive treatment of MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Additionally, HLP004, another proprietary NSA, is in Phase 2 for GAD. These candidates represent a novel approach to mental health treatment, aiming to activate serotonin pathways believed to promote neuroplasticity, which could offer durable improvements for patients.
The announcement comes at a critical time when the mental health landscape is evolving, and there is a growing demand for innovative therapies that go beyond traditional antidepressants. Helus Pharma's focus on NSAs could position it as a leader in this emerging field, and the CEO's presence at a prominent investment conference may attract attention from investors seeking opportunities in the mental health space. The company's commitment to addressing the large unmet need for people suffering from depression, anxiety, and other conditions is underscored by its extensive research portfolio and its operations across Canada, the United States, the United Kingdom, and Ireland.
Investors and industry observers will likely be keen to hear Halstead's insights on the company's clinical development plans, regulatory interactions, and potential timeline for commercialization. The fireside chat format allows for a more in-depth discussion of these topics, providing transparency and potentially boosting confidence in the company's strategy. Furthermore, the webcast and replay ensure that a broader audience can access the information, aligning with the company's efforts to engage with its investor community.
For more details about the conference and the company's progress, interested parties can visit the full press release at https://ibn.fm/1HSIo. Additionally, the latest news and updates relating to Helus Pharma are available in the company's newsroom at https://ibn.fm/HELP.
